Literature DB >> 26870294

DNA hypermethylation of the vimentin gene inversely correlates with vimentin expression in intestinal- and diffuse-type gastric cancer.

Hui Cong1, Ru-Yong Yao2, Zhen-Qing Sun3, Wen-Sheng Qiu1, Ya-Sai Yao4, Tong-Tong Feng4, Chao Xin4, Jun Liang1, L U Yue1.   

Abstract

The vimentin gene is a hallmark of epithelial-to-mesenchymal transition and has been observed to be overexpressed in various types of tumor cell line and tissue. Previous studies have reported correlations between vimentin DNA methylation levels and subsequent vimentin expression levels in solid tumors, including breast and colorectal cancer; however, to the best of our knowledge, such a correlation has not been reported for gastric cancer (GC) using Lauren classification. Therefore, the present study aimed to quantify DNA methylation levels of the vimentin gene using quantitative (q) methylation-specific polymerase chain reaction (PCR) in intestinal-type GC cell lines (MKN-28, AGS and MKN-1), diffuse-type GC cell lines (SGC-7901, SNU-5 and KATO III), the GES-1 immortalized human non-neoplastic gastric epithelial cell line, as well as in tumor and paratumor normal tissue samples. Furthermore, the present study analyzed the messenger RNA expression of the vimentin gene in these cell lines and tissues by reverse transcription-qPCR. A comparison of the clinicopathological features was conducted between patients, grouped according to the Lauren classification. The present study identified that the vimentin promoter region was hypermethylated in all GC cell lines and tumor tissue samples when compared with immortalized normal gastric epithelial cells and paratumor normal tissues. In addition, vimentin promoter methylation levels were observed to be higher in intestinal-type cell lines when compared with those of diffuse-type lines and tissues. Correspondingly, vimentin expression levels were lower in intestinal-type gastric cell lines compared with those of diffuse-type cell lines and tissues, and were lowest in the non-neoplastic gastric cell line and paratumor normal tissues. Patients with diffuse-type GC were on average younger (P=0.023), and exhibited higher tumor (P=0.020), node (P=0.032) and TNM classification of malignant tumor stage (P=0.039) than those with intestinal-type GC. Following treatment of AGS cells (which demonstrated the highest methylation level of the vimentin gene) with 5-aza-2'-deoxycytidine, vimentin expression was restored significantly. Thus, the present study revealed that vimentin promoter methylation levels are inversely correlated with vimentin expression levels in GC (according to Lauren classification). High levels of methylation in the vimentin gene promoter region may be involved in carcinogenesis and the development of GC, and may provide a novel molecular classification for GC.

Entities:  

Keywords:  DNA methylation; Lauren classification; epigenetic; gastric cancer; vimentin

Year:  2015        PMID: 26870294      PMCID: PMC4727186          DOI: 10.3892/ol.2015.3937

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  The Raf-1 kinase associates with vimentin kinases and regulates the structure of vimentin filaments.

Authors:  P Janosch; A Kieser; M Eulitz; J Lovric; G Sauer; M Reichert; F Gounari; D Büscher; M Baccarini; H Mischak; W Kolch
Journal:  FASEB J       Date:  2000-10       Impact factor: 5.191

2.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

3.  Structure and function of a vimentin-associated matrix adhesion in endothelial cells.

Authors:  M Gonzales; B Weksler; D Tsuruta; R D Goldman; K J Yoon; S B Hopkinson; F W Flitney; J C Jones
Journal:  Mol Biol Cell       Date:  2001-01       Impact factor: 4.138

4.  Aberrant vimentin methylation is characteristic of upper gastrointestinal pathologies.

Authors:  Helen Moinova; Rom S Leidner; Lakshmeswari Ravi; James Lutterbaugh; Jill S Barnholtz-Sloan; Yanwen Chen; Amitabh Chak; Sanford D Markowitz; Joseph E Willis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-07       Impact factor: 4.254

5.  Vimentin is secreted by activated macrophages.

Authors:  Nirit Mor-Vaknin; Antonello Punturieri; Kajal Sitwala; David M Markovitz
Journal:  Nat Cell Biol       Date:  2003-01       Impact factor: 28.824

Review 6.  Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication.

Authors:  Xiaojing Tang; Shuqing Chen
Journal:  Curr Drug Metab       Date:  2015       Impact factor: 3.731

Review 7.  Pathology and molecular biology of gastric cancer.

Authors:  Matti Vauhkonen; Hanna Vauhkonen; Pentti Sipponen
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006       Impact factor: 3.043

8.  Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition.

Authors:  Melissa G Mendez; Shin-Ichiro Kojima; Robert D Goldman
Journal:  FASEB J       Date:  2010-01-22       Impact factor: 5.191

Review 9.  Novel functions of vimentin in cell adhesion, migration, and signaling.

Authors:  Johanna Ivaska; Hanna-Mari Pallari; Jonna Nevo; John E Eriksson
Journal:  Exp Cell Res       Date:  2007-04-14       Impact factor: 3.905

10.  Endothelial cells assemble two distinct alpha6beta4-containing vimentin-associated structures: roles for ligand binding and the beta4 cytoplasmic tail.

Authors:  S M Homan; A M Mercurio; S E LaFlamme
Journal:  J Cell Sci       Date:  1998-09       Impact factor: 5.285

View more
  4 in total

1.  Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.

Authors:  Melissa B Pappalardi; Kathryn Keenan; Mark Cockerill; Wendy A Kellner; Alexandra Stowell; Christian Sherk; Kristen Wong; Sarath Pathuri; Jacques Briand; Michael Steidel; Philip Chapman; Arthur Groy; Ashley K Wiseman; Charles F McHugh; Nino Campobasso; Alan P Graves; Emma Fairweather; Thilo Werner; Ali Raoof; Roger J Butlin; Lourdes Rueda; John R Horton; David T Fosbenner; Cunyu Zhang; Jessica L Handler; Morris Muliaditan; Makda Mebrahtu; Jon-Paul Jaworski; Dean E McNulty; Charlotte Burt; H Christian Eberl; Amy N Taylor; Thau Ho; Susan Merrihew; Shawn W Foley; Anna Rutkowska; Mei Li; Stuart P Romeril; Kristin Goldberg; Xing Zhang; Christopher S Kershaw; Marcus Bantscheff; Anthony J Jurewicz; Elisabeth Minthorn; Paola Grandi; Mehul Patel; Andrew B Benowitz; Helai P Mohammad; Aidan G Gilmartin; Rab K Prinjha; Donald Ogilvie; Christopher Carpenter; Dirk Heerding; Stephen B Baylin; Peter A Jones; Xiaodong Cheng; Bryan W King; Juan I Luengo; Allan M Jordan; Ian Waddell; Ryan G Kruger; Michael T McCabe
Journal:  Nat Cancer       Date:  2021-09-27

2.  Immunohistochemical Expression of Epithelial-Mesenchymal Transition Markers in Early Gastric Cancer: Cancer Tissue versus Noncancer Tissue.

Authors:  Hee Jae Jung; Su Jin Hong; Shin Hee Kim
Journal:  Clin Endosc       Date:  2019-05-22

3.  Anti-fibrotic properties of an adiponectin paralog protein, C1q/TNF-related protein 6 (CTRP6), in diffuse gastric adenocarcinoma.

Authors:  Yoshinori Iwata; Itaru Yasufuku; Chiemi Saigo; Yusuke Kito; Tamotsu Takeuchi; Kazuhiro Yoshida
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

4.  Vimentin as a target for the treatment of COVID-19.

Authors:  Zhenlin Li; Denise Paulin; Patrick Lacolley; Dario Coletti; Onnik Agbulut
Journal:  BMJ Open Respir Res       Date:  2020-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.